Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

CA (ON): Canadian firm receives Health Canada approval for expansion

VIVO Cannabis Inc. has announced that the Company's wholly-owned subsidiary, ABcann Medicinals Inc., has received approval from Health Canada to begin cultivation in the expansion of its Vanluven Road facility in Napanee, resulting in a doubling of the Company's Ontario cultivation capacity. "Cultivation in the expanded area will commence immediately", the company says. 

"The expansion includes production and product development space built to GMP standards. A CO2 extraction suite for production of concentrates has been incorporated into the facility and is expected to be brought on-line mid 2019. VIVO's current production capacity is now over 5,000 kilograms and is anticipated to further increase to 11,000 kilograms later in 2019 following the completion and licensing of on-going, fully-funded expansion projects in Hope, B.C. and Napanee, Ontario. This capacity will be augmented by several thousand additional kilograms sourced from third-party cultivators that meet VIVO's rigorous quality standards", the company continues. 

"Through our internal expansion projects (including indoor facilities, seasonal greenhouses and outdoor growing) and certified third-party partners, we are well-positioned to increase our offering in Canada's medical and adult-use markets, including launching new formats such as edibles, concentrates and precisely-dosed medical products when they are permitted by regulations," says Barry Fishman, Chief Executive Officer of VIVO.

Mr. Fishman adds, "The GMP certification of our Vanluven expansion, expected later this year, will enable us to service the growing international medical cannabis market. We are excited to build on our success by introducing new high-margin, value-added products which leverage our increased production capabilities and tap into the user insights gained from our vast Harvest Medicine Clinic patient network."

For more information:
VIVO Cannabis  


Publication date: